Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

3-D Models Devised to Simulate Patients’ Tumors

Gioeli lab group

A university lab is teaming up with a local biotechnology company to develop realistic models of tumors from individual cancer patients, enabling more personalized treatment options. . . . → Read More: 3-D Models Devised to Simulate Patients’ Tumors

Trial Underway Testing Universal Flu Vaccine

Influenza virus

A clinical trial is recruiting participants to test a vaccine to protect against a variety of influenza strains, instead of today’s vaccines designed to prevent infections from specific strains expected in a given year. . . . → Read More: Trial Underway Testing Universal Flu Vaccine

New Cell Therapy Company Raises $58.5M in Early Funds

Investment graphic

A start-up enterprise is discovering therapies to address a variety of disorders that result from faulty cell degradation processes known as autophagy, which when functioning normally contribute to cell health. . . . → Read More: New Cell Therapy Company Raises $58.5M in Early Funds

Cellectis, Wyss Inst. Partner on Recoding Human Genome

DNA puzzle

A bioengineering center at Harvard University and a biotechnology company are creating a process for genetically editing human cell lines to produce virus-resistant synthetic proteins for research and therapies. . . . → Read More: Cellectis, Wyss Inst. Partner on Recoding Human Genome

Platform to Integrate Robotics, Synthetic Biology, A.I.

Microbes

Two companies are developing a new model for a cloud-based platform that makes possible automated collaborative research with artificial intelligence in synthetic biology. . . . → Read More: Platform to Integrate Robotics, Synthetic Biology, A.I.

Gene Therapy Biotech Acquired in $8.7 Billion Deal

A biotechnology enterprise developing gene therapies for rare inherited diseases and neurological disorders is being acquired by pharmaceutical company Novartis AG for $8.7 billion. . . . → Read More: Gene Therapy Biotech Acquired in $8.7 Billion Deal

Lilly, Cell Implants Start-Up Partner on Diabetes

Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases. . . . → Read More: Lilly, Cell Implants Start-Up Partner on Diabetes

New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells. . . . → Read More: New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

Cough Suppressant Produced from Engineered Yeast Cells

A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast. . . . → Read More: Cough Suppressant Produced from Engineered Yeast Cells

Antibodies Licensed for Multi-Target Immunotherapies

MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets. . . . → Read More: Antibodies Licensed for Multi-Target Immunotherapies